Emerging technologies in the delivery of erythropoietin for therapeutics.
about
EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and β-catenin to foster vascular integrity during experimental diabetes.Translating cell survival and cell longevity into treatment strategies with SIRT1SIRT1: new avenues of discovery for disorders of oxidative stressHuman erythropoietin gene delivery using an arginine-grafted bioreducible polymer system.A perspective on bioactive cell microencapsulation.CNS drug targeting: have we travelled in right path?
P2860
Emerging technologies in the delivery of erythropoietin for therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging technologies in the delivery of erythropoietin for therapeutics.
@en
Emerging technologies in the delivery of erythropoietin for therapeutics.
@nl
type
label
Emerging technologies in the delivery of erythropoietin for therapeutics.
@en
Emerging technologies in the delivery of erythropoietin for therapeutics.
@nl
prefLabel
Emerging technologies in the delivery of erythropoietin for therapeutics.
@en
Emerging technologies in the delivery of erythropoietin for therapeutics.
@nl
P2093
P2860
P356
P1476
Emerging technologies in the delivery of erythropoietin for therapeutics.
@en
P2093
Ainhoa Murua
Gorka Orive
José Luis Pedraz
Rosa M Hernández
P2860
P304
P356
10.1002/MED.20184
P577
2011-03-01T00:00:00Z